Moderna, Inc. (MRNA) saw its stock price surge 5.04% during intraday trading on Wednesday.
The sharp rise follows reports that a key U.S. federal vaccine advisory panel has abandoned a push to potentially stop recommending mRNA COVID-19 vaccines. The panel, under Health and Human Services Secretary Robert F. Kennedy Jr., is no longer moving forward with the plan, according to the Washington Post.
This development removes a significant regulatory overhang for Moderna, a leading producer of mRNA vaccines. The news suggests continued institutional support for the technology, which is central to the company's business model.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments